On September 18, XTALPI rose 7.03% in regular trading, trading at HK$7.41/share, with turnover of HK$112 million. The rally was driven by the announcement that the company's wholly-owned subsidiary has entered into a drug discovery collaboration agreement with Stanford University.
According to the announcement released on September 17, LCC Technologies Ltd., a wholly-owned subsidiary of XTALPI, signed the agreement with the Board of Trustees of Stanford University. Under the terms, novel biological insights from Stanford's disease biology research will be integrated into LCC Technologies' proprietary PACE small-molecule drug discovery platform to evaluate their potential for translation into therapeutic compounds. A joint steering committee has been established to advance project evaluation and translational efforts, with Stanford's principal investigators able to propose projects based on their research.
The company stated that this collaboration reinforces its strategic positioning in AI- and automation-driven drug discovery and lays the groundwork for participation in early-stage programs. Within the Life Sciences Tools & Services sector, peers also showed strength, with INSILICO up 6.33%, GENSCRIPT BIO up 5.53%, WUXI APPTEC up 1.41%, WUXI BIO up 1.1%, and WUXI XDC up 0.85%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments